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Introduction
In the last decade noncoding RNAs have emerged as a novel 
landscape of regulatory networks and have been extensively 
studied in human cancer.1,2 Among noncoding RNAs, microR-
NAs (miRNAs) have been described as deeply dysregulated 
in cancer3–6 and have raised special interest for therapy.7–22 
In fact, synthetic mimics of tumor suppressor miRNAs have 
been investigated for replacement strategies in several 
preclinical cancer models23–29 and the first cancer-targeted 
miRNA drug, MRX34, a liposome-based miR-34a mimic is 
currently under phase 1 investigation in cancer patients. By 
a different approach, the use of anti-oncopromoting miRNAs 
has been pursued for clinical translation, firstly by antisense 
oligonucleotides (ASOs) or short interference RNA30,31 and 
then, by a new generation of ASOs or Gapmers, which offer 
advantages in terms of pharmacokinetics (PK) and phar-
macodynamics. It became evident that the real challenges 
for the therapeutic use of antisense molecules are their bio-
logical stability, target affinity, biodistribution as well as the 
ability to activate RNase H function, with reduced off-target 
toxicity. Among the modified oligonucleotides, the so called 
“second generation” phosphorothioate (PS) locked nucleic 
acid (LNA)-based oligonucleotides have demonstrated 
high affinity for the specific complementary strand (i.e., 
mature miRNA), with obvious advantages in term of target 
specificity.32,33 LNA-oligonucleotides have been success-
fully used in in vitro and in vivo studies and demonstrated 
great potential as inhibitors of small RNA targets.12,34–36 The 
high target affinity and specificity reduces nonhybridization-
based interactions and related toxicities, making them suit-
able for systemic delivery.33 Moreover, LNA-oligonucleotides 
are stable for years under refrigeration, are highly soluble 
in water and can be diluted and injected in vivo in saline 
solution.12,34–36 However, at the present, poor information is 
available on the PK of LNA-oligonucleotides after systemic 
administration, either by intravenous (i.v.) infusion or intra-
peritoneal (i.p.) injection, due to the complex bioanalyticals 
that are needed for PK evaluation. The bioavailability of these 
compounds relies in their systemic distribution and retention 
by tissues: such processes involve surface protein interac-
tions and endocytosis, thus finally lead to cell internalization 
and excretion.33
In a previous report, we demonstrated the therapeutic 
activity of a novel 13-mer LNA-miR-221 inhibitor (LNA-i-
miR-221) in preclinical models of multiple myeloma (MM).12,20 
Here we studied the LNA-i-miR-221 bioavailability profile 
following intravenous (i.v.) administration at antitumor dose 
in NOD.SCID mice and nonhuman primates. For the lack of 
standardized methodology, we developed a novel approach 
for the detection of LNA-i-miR-221 animal biofluids as well 
as in mouse tissues and tumor xenografts. Moreover, we 
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Locked nucleic acid (LNA) oligonucleotides have been successfully used to efficiently inhibit endogenous small noncoding 
RNAs in vitro and in vivo. We previously demonstrated that the direct miR-221 inhibition by the novel 13-mer LNA-i-miR-221 
induces significant antimyeloma activity and upregulates canonical miR-221 targets in vitro and in vivo. To evaluate the LNA-
i-miR-221 pharmacokinetics and pharmacodynamics, novel assays for oligonucleotides quantification in NOD.SCID mice and 
Cynomolgus monkeys (Macaca fascicularis) plasma, urine and tissues were developed. To this aim, a liquid chromatography/
mass spectrometry method, after solid-phase extraction, was used for the detection of LNA-i-miR-221 in plasma and urine, while 
a specific in situ hybridization assay for tissue uptake analysis was designed. Our analysis revealed short half-life, optimal 
tissue biovailability and minimal urine excretion of LNA-i-miR-221 in mice and monkeys. Up to 3 weeks, LNA-i-miR-221 was still 
detectable in mice vital organs and in xenografted tumors, together with p27 target upregulation. Importantly, no toxicity in the 
pilot monkey study was observed. Overall, our findings indicate the suitability of LNA-i-miR-221 for clinical use and we provide 
here pilot data for safety analysis and further development of LNA-miRNA-based therapeutics for human cancer.
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studied the biological activity of LNA-i-miR-221 in animals 
and we searched for tissue and behavioral toxicity. Overall, 
our results provide novel information relevant for the design 
of oligonucleotide-based cancer therapeutics in the perspec-
tive of first-in-human regulatory studies.
Results
LNA-i-miR-221 is well tolerated in mouse
We first investigated the effect induced by LNA-i-miR-221 
in mouse behavior or by pathologic analysis of vital organs 
including liver, kidney, and heart. Animals underwent one 
course of treatment, which includes injections on days 1, 4, 
8, 15, and 22 with two different doses. We selected 25 mg/
kg as investigation dose based on our previous findings.12 
Thus we derived a fourfold higher dose of 100 mg/kg specifi-
cally selected to investigate tissue toxicity in mice. The ani-
mals did not show behavioral changes. One week following 
the completion of one treatment course, animal tissues were 
retrieved and hematoxylin and eosin stained. As shown in 
Figure 1, no morphological changes or abnormal findings 
were detected in retrieved tissues, confirming the absence 
of acute toxicity or inflammation. No toxicity even at highest 
dose was observed, indicating a good safety profile of LNA-
i-miR-221 in mice.
LNA-i-miR-221 is detectable in xenografted tumors and 
mouse organs by in situ hybridization
To evaluate the tissue bioavailability of LNA-i-miR-221, we 
assessed the localization of LNA-i-miR-221 by in situ hybrid-
ization (ISH) using a specific LNA antisense probe to LNA-
i-miR-221 (miR-221i) in formalin-fixed paraffin-embedded 
tissue samples retrieved from single injection- (25 mg/kg of 
LNA-i-miR-221) treated animals after 2 or 7 days. Intense 
miR-221i ISH signal was detected in all organs analyzed 
including liver, kidney (Figure 2), heart, bone marrow, brain, 
and tumor samples retrieved from all treated mice  (Figure 3, 
line I and II), whereas signal was not detectable from 
untreated animals (Figure 3 line III). ISH from LNA-i-miR-221 
treated or untreated animals was validated by parallel stain-
ing with an LNA probe toward endogenous microRNA-126 
(miR-126) (see Supplementary Figure S1). miR-126 was 
indeed detected in all samples and with staining intensity 
in endothelial cells independent from treatment, indicating 
that all tissue specimens had been prepared uniformly and 
therefore, the ISH signal detected with the miR-221i probe 
indeed reveals the genuine LNA-i-miR-221. A reduced miR-
126 ISH signal was detected in tumor tissues probably due 
to a lower miR-126 expression by human MM cells. Intense 
LNA-i-miR-221 ISH signal was detected in liver samples, 
particularly in spindle-shaped cells, presumable liver macro-
phages/Kupfer cells and/or endothelial cells, but also epithelial 
liver cells had positive ISH signal (Figure 3a). In kidney tissue 
sections, LNA-i-miR-221 ISH signal was detected in tubules 
(Figure 3b). In heart samples, LNA-i-miR-221 ISH signal was 
detected in spindle-shaped cells presumably capillary endo-
thelial cells (Figure 3c). In bone marrow sections, the ISH 
signal was detected in a subset of spherical cells (Figure 3d). 
In all organs retrieved from LNA-i-miR-221 treated animals, a 
LNA-i-miR-221 ISH specific signal was detected. An intense 
signal was detected also in xenograft MM tumor samples, 
demonstrating adequate tumor uptake (Figure 3e). Overall 
these findings demonstrated the detection of miR-221i/LNA-i-
miR-221 heteroduplex within cells, with prevalent perinuclear 
localization in most tissues. No obvious differences in ISH 
signal were seen in tissues from animals sacrificed 2 or 7 
days after a single 25 mg/kg dose of LNA-i-miR-221. Our find-
ings indicate that ISH is a suitable technique for detection of 
LNA-i-miR-221 in normal and tumor tissues.
Long-lasting LNA-i-miR-221 detection in mouse tissues
In order to evaluate bioavailability of LNA-i-miR-221, we per-
formed a mouse study to analyze the inhibitor in different 
tissues retrieved from animals which had undergone to one 
course of treatments (days 1, 4, 8, 15, 22) with LNA-i-miR-221 
at doses of 25 mg/kg or fourfold higher dose (100 mg/kg). 
Animals were then sacrificed 1 week or 3 weeks after last 
injection, and vital organs including liver, kidney, heart, bone 
marrow, and xenografted tumors were collected. ISH showed 
variations in staining intensity comparing various organs at 
different time points, with a signal reduction within 3 weeks 
from last treatment. Specifically, the ISH signal was weaker in 
the heart and xenograft tumors after 3 weeks from last injec-
tion (25 mg/kg), while liver, kidney, and bone marrow main-
tained an intense signal up to 3 weeks from last treatment at 
both doses (Figure 4, line II and S2). No obvious difference 
in the LNA-i-miR-221 staining intensity was found among ani-
mals receiving single treatment (Figure 3) or all scheduled 
treatments (Figure 4).
LNA-i-miR-221 ISH analysis in brain
To evaluate if LNA-i-miR-221 is detectable in the brain tis-
sues, we performed ISH on samples retrieved from six mice, 
2 and 7 days after a single injection at the dose of 25 mg/kg. 
Positive ISH signal was confined to the capillary glial cells 
and endothelial cells of the venous capillaries in arachnoid 
meninges, whereas all neurons were negative (Figure 5a,b). 
No ISH signal was seen in brain tissue from untreated ani-
mals with miR-221i probe assay (Figure 5c) or in treated ani-
mals with miR-221i scramble probe assay (Figure 5d). Liver 
samples from the same animals were collected and analyzed 
to demonstrate the successful delivery of LNA-i-miR-221 in 
these animals (Figure 5f). Additional images of brain ISH are 
included in Supplementary Figure S2. Our results indicate 
that LNA-i-miR-221 does not cross the blood-brain barrier 
(BBB).
P27 is upregulated in mouse tissues after LNA-i-miR-221 
treatment
A major goal in the monitoring of an oligonucleotide-based 
therapy is the demonstration of its biological activity in vivo. At 
this aim, we investigated whether LNA-i-miR-221 efficiently 
inhibits miR-221 in tissues by modulation of p27 expres-
sion, the major miR-221 canonical target. We analyzed by 
immunohistochemistry, normal tissues, and xenografted 
tumors retrieved from mice. We confirmed the effectiveness 
of our oligonucleotide in functional inhibition of miR-221. 
Interestingly, this effect was observed till 3 weeks after the 
last injection at dose of 25 mg/kg, as shown by increased 
p27 expression in liver and kidney (90% of positive cells in 
www.moleculartherapy.org/mtna
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both tissues after 1 week; 80 and 90%, respectively, after 3 
weeks) (Figure 6b,c,e,f), as compared with control animals 
(60 and 50%, respectively) (Figure 6a,d). In the heart, we 
did not detect any change in p27 expression, as assessed by 
30% of positive cells in all animal groups (Figure 6g,i), while 
xenografted tumors showed an increase of positive cells from 
20% in the control group (Figure 6l) to 40% after 1 week 
and 60% after 3 weeks from the last injection (Figure 6m,n). 
The p27 signal intensity was strongly homogeneous in all 
analyzed specimens. Interestingly, the increase of p27 did 
Figure 1  Toxicity evaluation of Locked Nucleic Acid (LNA) LNA-i-miR-221 in mouse organs. Hematoxylin and eosin (H&E) staining of 
heart, liver, and kidney retrieved from mouse 1 week after one cycle (day 1, 4, 8, 15, and 22) of treatment. a, b, c, show representative areas 
of heart retrieved after saline (a), 25 mg/kg LNA-i-miR-221 (b) or 100 mg/kg course of treatments. d, e, f show representative areas of liver, 
while g, h, i kidney areas, after saline (d,g), 25 mg/kg (e,h) or 100 mg/kg (f,i) LNA-i-miR-221 treatment. Frames a, b, c, d, e, f are 100× while 
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Figure 2 In situ hybridization (ISH) analysis of LNA-i-miR-221. Serial sections from formalin-fixed paraffin-embedded (FFPE) tissue 
samples of NOD.SCID mouse kidney after a single i.p. (intraperitoneal) injection of 25 mg/kg LNA-i-miR-221 (a–d) or saline (e), processed 
by ISH with Locked Nucleic Acid (LNA) probes for LNA-i-miR-221 (a, b, e), miR-126 (c), and miR-221 scramble (d). Intense LNA-i-miR-221 
ISH signal is detectable in tubules at both low (5 nmol/l) and high (20 nmol/l) probe concentrations (a, b), whereas the probe results in no ISH 
signal in saline-treated kidney. The positive control probe, miR-126, stains endothelial cells including capillaries in the glomeruli (c), and only 
background staining is seen by the use of the scramble negative control probe (d).
miR-221i, 5 nmol/l
miR-126, 30 nmol/l
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not result in toxicity on normal liver where Ki67 was never 
detected (see Supplementary Figure S9). Conversely, the 
increase of p27 in xenografted tumors was associated with 
reduction of Ki67 positive cells 1 week after the last treatment 
(15% of positive cells) as compared with untreated tumors 
(30%, Supplementary Figure S9d,e). However, the percent-
age of Ki67-positive cells increased again 3 weeks after last 
treatment (30%; Supplementary Figure S9f), probably for 
resumed cell proliferation even though the persistence of the 
inhibitor in tumor cells, assessed by ISH (Figure 4). In these 
Figure 3 In situ hybridization (ISH) detection of LNA-i-miR-221 in mouse tissues. LNA-i-miR-221 ISH on sections from organs retrieved 
from mice after 2 (I) and 7 (II) days of a single intraperitoneal (i.p.) injection of the LNA-i-miR-221 at therapeutic dose of 25 mg/kg or saline 
(III). Tissue sections from LNA-i-miR-221-treated (I and II) or saline-treated (III) liver (a), kidney (b), heart (c), bone marrow (d), and NCI-H929 
xenograft tumor (e) samples after miR-221i probe hybridization. LNA-i-miR-221 staining is detectable in macrophages and/or vessels (liver 
and tumor), tubules (kidney), probably vascular cells (heart), subpopulation of hematopoietic cells (bone marrow). Bars: Liver, kidney, and 





Kidney Heart TumorBone marrow
a b c d e
Figure 4 Long-lasting LNA-i-miR-221 signal in mouse tissues. LNA-i-miR-221 in situ hybridization (ISH) in NOD.SCID mouse organs after 
injection of therapeutic doses of LNA-i-miR-221 at 25 mg/kg at days 1, 4, 8, 15, and 22. The organs were harvested at 1 week (I) or 3 weeks 
(II) after last injection. The staining intensity is high both after 1 and 3 weeks: (a) liver and (b) kidney maintain an intense signal throughout the 
period, while a slightly weaker signal is detectable in heart (c), bone marrow (d) and tumor tissue (e) 3 weeks after last dose. No ISH signal 
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same specimens, we also evaluated apoptosis by Terminal 
deoxynucleotidyl transferase (TdT) dUTP Nick-End Label-
ing (TUNEL) assay. Normal liver sections from all animals 
showed the absence of apoptotic events (see Supplementary 
Figure S10a–c), while MM xenografts showed 0.1% of 
apoptotic cells in untreated mice, 15% and 5%, respectively 
1 and 3 weeks after last injection in treated animals (see 
 Supplementary Figure S10 d–f). Overall, our data indicate 
that LNA-i-miR-221 efficiently antagonizes miR-221 activity 
in tumors, as also demonstrated by the inverse correlation of 
miR-221 and p27 mRNA expression assessed by  quantitative 
real time polymerase chain reaction (see  Supplementary 
Figure S11). In addition, 3 weeks after ending the treatment, 
an increase of miR-221 and a reduction of p27 expression 
was detected, indicating release from the inhibitory activity, 
as also demonstrated by Ki67 increase. Interestingly, the 
increased expression of p27 in vital organs did not result 
in abnormal morphology, as assessed by hematoxylin and 
eosin staining (Figure 1), nor resulted in apoptosis, as evalu-
ated by TUNEL (see Supplementary Figure S10).
LNA-i-miR-221 is detectable in animal plasma and urine
Short oligonucleotides are not suitable for quantification with 
quantitative real time polymerase chain reaction. Moreover, 
ASOs, such as LNA-PS derivatives, require a high degree of 
quality control and identification of minor impurities. Until recently, 
analytical tools have been limited to high-performance liquid 
chromatography and gel electrophoresis, but the qualitative 
conclusions were based on retention or migration times and not 
sufficient for absolute identification. A number of high-resolution 
separation systems have been developed for oligonucleotides 
detection in biological fluids, including electrospray ionization 
mass spectrometry. In our feasibility study, we first used plasma 
from treated mouse to set-up a LNA-i-miR-221 quantification 
method, based on mass spectrometry. To this aim aliquots of 120 
µl of plasma from mouse blood samples, treated with a single 
dose of 25 mg/kg with LNA-i-miR-221, were used for prepara-
tion of LC-MS/MS injection solution. LNA-i-miR-221 concentra-
tion were calculated in the range of 25–2,500 ng/ml, based on 
calibration curve fitted by weighted linear regression function (l/
x2), with at least 75% of back-calculated concentrations within 
15% accuracy. In these conditions, in mouse plasma the limit 
of quantification was fixed at 25 ng/ml. The retention time for 
LNA-i-miR-221 was 0.45 minutes (see  Supplementary Figure 
S3a) and we drown a linear (r = 0.9943) calibration curve (see 
 Supplementary Figure S3b) that we used for quantification of 
LNA-i-miR-221 in mouse and monkey studies. Likewise, 10 µl of 
monkey urine were used for preparation of LC-MS/MS injection 
solution. In these conditions LNA-i-miR-221 concentration was 
calculated in the range of 75–5,000 ng/ml, based on calibration 
curve fitted by weighted linear regression function (l/x2), with at 
least 75% of back-calculated concentrations within 20% accu-
racy. Limit of quantification in monkey urine was fixed at 75 ng/
ml. In Supplementary Figure S3 is reported typical LC-MS/MS 
chromatograms obtained for urine samples and an example of 
calibration curve.
Figure 5 LNA-i-miR-221 in situ hybridization (ISH) signal in mouse brain. LNA-i-miR-221 ISH in brain samples retrieved from mice after 2 
(a) or 7 days (b) of a single intraperitoneal (i.p.) injection of the LNA-i-miR-221 at the therapeutic dose of 25 mg/kg or saline (c). Brain sections 
from LNA-i-miR-221 (a, b) or saline treated (c) animals using miR-221i probe (a, b, c), scramble negative control probe, (d) or positive control 
probe against miR-126 (e). Intense staining is seen in the liver (f) from the same mouse as in a. No nervous parenchyma showed detectable 
LNA-i-miR-221 ISH signal.
2 days-25 mg/kg
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
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Pharmacokinetic profile of LNA-i-miR-221 in mouse
Analysis of the mouse PK following a single injection of 
25 mg/kg of LNA-i-miR-221 indicated a plasma concentra-
tion peak at a Tmax of 1.5 hours with a Cmax of 1,110 ng/ml 
(Figure 7a). After 3 hours from i.v. injection the plasma con-
centration was reduced to ~ 60% and after 6–24 hours the 
molecule was no more detectable (Figure 7b ). The t1/2 of the 
molecule was calculated as 1.05 hours. The plasma exposure 
Figure 6 miR-221 inhibition by LNA-i-miR-221 induces p27 upregulation in mouse tissues. Immunohistochemistry (IHC) of p27 in liver 
and kidney mouse tissue from untreated mice (a, d) and from mice that underwent a course of 25 mg/kg LNA-i-miR-221 treatment retrieved 
after 1 (b,e) or 3 (c,f) weeks from last treatment. Increased p27 expression is showed in representative image of liver and kidney (80 and 90% 
of positive cells, respectively) from treated animals, compared with the same control tissue (60 and 50%) in liver and kidney, respectively. 
Heart tissue of untreated (g) and treated animals showing the same low expression of p27 (30%) at both time-points evaluated (h,i). MM 
xenograft tumors showed an increase of positive cells form 20% in the saline treated animals (l) to 40% after 1 week (m) and 60% after 
3 weeks (n) from last injection. Positive cells were counted in 10 high-magnification random fields of the most representative areas; the degree 
of immunostaining for each antibody was expressed as the percentage of positive cells among the total number of cells. Representative image 
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of the molecules shown an AUC last of 1,730 ng*hour/ml. 
The PK study in mice demonstrated a rapid serum clear-
ance of LNA-i-miR-221 and a rapid uptake from cells, as 
also demonstrated by the strong signal detected by ISH in 
xenografted tumors after 12 hours of single LNA-i-miR-221 
injection  (Figure 7c,d).
LNA-i-miR-221 is nontoxic in Cynomolgus monkey
To further evaluate the safety profile of LNA-i-miR-221, we 
designed a pilot toxicity study in nonhuman primates. To this 
aim five non-naive Cynomolgus monkeys were used for the 
study and represented five treatment “groups” including, con-
trol, low, mid, high dose, and PK study group. Animals under-
went five injections (on days 1, 4, 8, 15, and 22) with 0, 2.5, 
6.25, and 8.75 mg/kg of LNA-i-miR-221, respectively. The 
animal of the PK group received a single dose of 8.75 mg/
kg, the highest dose evaluated, defined as maximum toler-
ated dose in our study. Specifically, the mid dose (6.25 mg/kg) 
tested in monkey was selected, because it was equivalent to 
the therapeutic dose in xenografted mice (25 mg/kg) (Preclin-
ical Safety Evaluation of Biotechnology-derived Pharmaceu-
ticals S6 (R1), Parent Guideline, 1997). Observations were 
done daily (food and water consumption; behavior; eyes, and 
skin signs) or weekly (body weight) or prior to the treatment 
(hematology or serum biochemistry; for detailed evaluation, 
see supplemental material). After completion of the treatment 
period in the first four animals, no changes were observed 
on behavior of treated animals, including body weight and 
food consumption, as compared with the control (see Sup-
plementary Figure S4). Moreover, no changes in heart rate 
were recorded in all animals in the time frame between the 
first and the last injection, when compared with the predose 
values (data not shown). Blood evaluations included in the 
study are listed in Supplementary Table S1. All the recorded 
values confirmed the safety profile of LNA-i-miR-221 in mon-
keys, as shown by hematology, coagulation, liver and kid-
ney parameters (see Supplementary Figure S5–S7). All 
data before and after treatments for each animal are listed 
in Supplementary Table S2. The findings indicated normal 
liver and kidney function in all treated animals. Moreover, 
activation of the immune response was investigated by flow 
cytometer evaluation of the plasma cytokines mostly involved 
in inflammation. LNA-i-miR-221 treatment progressively 
reduced plasma levels of IL-8, MCP-1, and IL-6, suggesting 
anti-inflammatory activity. No changes in plasma levels of 
TNF-α, IFN-γ, and IL-4 could be detected. These cytokines 
remained below the detection level (< 10 pg/ml, Supplemen-
tary Figure S8) during treatments.
The animal included in the PK study (#5) received a sin-
gle maximum tolerated dose of LNA-i-miR-221. Plasma and 
urines were collected from this animal. Figure 8 shows the 
plasma PK profile. LNA-i-miR-221 plasma concentration of a 
Figure 7 Pharmacokinetics (PK) profile of LNA-i-miR-221 in mice. (a) Plot of plasma concentrations at different time-points for LNA-i-
miR-221 indicates a rapid plasmatic clearance from 1.5 to 6 hours after single dose injection (25 mg/kg), followed by a distribution phase, till to 
almost no detectability 6 hours after injection; (b) plasma LNA-i-miR-221 concentration (ng/ml) at each time point from 1.5 to 24 hours; (c–d) 
ISH for LNA-i-miR-221 in xenograft tumors of untreated (c) and treated animals (d) retrieved after 12 hours of single injection of LNA-i-miR-221 
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single high dose (8.75 mg/kg/day) peaked at a Tmax of half an 
hour with a Cmax of 23,600 ng/ml (Figure 8a,c). After 1 hour 
from i.v. injection, LNA-i-miR-221 plasma concentration was 
reduced to ~ 60% and after 6 hours, it was no more detect-
able. The plasma exposure of LNA-i-miR-221 showed an 
AUC-last of 49,300 hour*ng/ml and C0 of 61,400 ng/ml. The 
t1/2 of the molecule in monkey study was 12.83 hours. The 
monkey urine PK evaluation was performed on samples col-
lected in a four time-range from 2–48 hours. For each interval 
the urine volumes and LNA-i-miR-221 concentrations were 
recorded. LNA-i-miR-221 excreted in urine was quantified 
=0.68 mg in 48 hours, mostly in the first 6 hours (0.413 mg), 
with a total urinary recovery of ~2.68% of the total amount 
injected (25,375 mg). Specifically, the LNA-i-miR-221 uri-
nary concentration/time-points plot showed the excretion of 
9,394.57 ng/ml (1.63% of recovery) in the first range-time 
(2–6 hours) in 44 ml of urine. During the other 3 time-points, 
LNA-i-miR-221 concentrations were lower (Figure 8b,d). 
Overall these PK findings demonstrated a rapid serum clear-
ance of LNA-i-miR-221, with maximum tissues uptake and 
minimum urinary excretion.
Discussion
The basic strategy of miRNA therapeutics relies on the ability 
to efficiently replace or sequester endogenous miRNAs dys-
regulated in human cancer. Different chemical modifications 
have been recently introduced in oligonucleotides synthesis 
to improve stability and specificity which, in turn, strengthen 
their biomodulatory activity. It is now well established that 
LNA-based ASOs ensure high potency and affinity as inhibi-
tors of upregulated onco-miRNA, so that this class of com-
pounds are presently approaching cancer treatment in the 
clinics.34,36–40 However, one of the major issues in the aim of 
clinical translation has been the lack of quantitative assays 
for detection of LNA-miRNA inhibitors in biological fluids and 
tissues, which is relevant for PK and pharmacodynamics 
investigations and therefore for the design of clinical studies. 
Among available technologies for qualitative and quantitative 
evaluation, LC combined with MS is the method-of-choice for 
the detection of oligonucleotides in body fluids.41 Insufficient 
PK and poor cellular uptake are the main hurdles for suc-
cessful therapeutic development of oligonucleotide-based 
therapeutics. Second generation ASOs, including LNA-mix-
mers, following systemic administration, have rapid distribu-
tion, long-terminal half-life and plasma clearance, primarily 
due to extensive distribution in tissues.33 However, few data 
are presently available on the use of LC/MS for the study of 
LNA-miRNA inhibitors. To shed light on this important point, 
we used an ultra-high pressure LC-MS/MS protocol follow-
ing solid-phase extraction, which allows quantification of very 
low amounts of LNA-miR-221 inhibitor by the use of small 
volumes of mouse and monkey plasma as well as of mon-
key urine. In our mouse study, we observed that the 13-mer 
Figure 8 Pharmacokinetics (PK) profile of LNA-i-miR-221 in monkey study. (a) Plot of plasma concentration at different time-points for 
LNA-i-miR-221 indicates a rapid plasmatic clearance from 0.5 to 48 hours after single dose injection (875 mg/kg), followed by distribution 
phase, till to almost no detectablility after 48 hours; (b) plot of urine concentration versus four range of urine collection spanning from 2 hours 
to 48 hours, showing that most LNA-i-miR-221 excretion occurred within 6 hours; (c) plasma LNA-i-miR-221 concentration (ng/ml) at each 



































































































2–6 hours 9394.57 44.00 0.413 1.63
6–12 hours 3529.51 0.90 0.003 0.01
12–24 hours 3583.18 38.00 0.136 0.54
24–48 hours 3415.30 38.00 0.130 0.51
Total 0.68 mg 2.69%
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LNA-i-miR-221 is rapidly distributed into systemic circula-
tion. Following injection at therapeutic doses, a peak plasma 
concentration (Cmax) at 1.5 hour was detected. After reaching 
Cmax, plasma concentration declines after the fast initial distri-
bution phase (distribution half-life of about 3–4.5 hours), then 
a terminal elimination phase starting from ~ 4.5 hours with 
very low plasma concentration. Six hours after the treatment 
LNA-i-miR-221 became almost undetectable in the mouse 
plasma. Similarly, in Cynomolgus monkeys, following i.v. infu-
sion of a single dose of 8.75 mg/kg of LNA-i-miR-221, we 
observed again the peak of Cmax after 0.5 hour and its rapid 
decline in the plasma, where the concentration was reduced 
more than 10-folds in 1.5 hours from the peak. Consistent 
with the plasma distribution profile dominating plasma expo-
sure and clearance of the second generation ASOs, partial 
area plasma AUC(0.5–6 hours) values of LNA-i-miR-221 represent 
73.8% of AUC-last (0–48 hours) values. We could conclude that 
LNA-i-miR-221, evaluated in two different species by LC-MS/
MS showed a similar PK profile.
It has been demonstrated that second generation ASOs in 
plasma are mostly bound to plasma proteins which reduce the 
glomerular filtration and urine excretion.42 According to these 
findings, only a minimal amount (0.68 mg, 2,679%) of the 
intact LNA-i-miR-221, after a single active dose (25,375 mg), 
was recovered in monkey urines. On the other hand, the low 
affinity binding of ASOs to plasma proteins favors the bind-
ing to cell surface proteins with consequent extensive cellular 
uptake.43 This is confirmed by our ISH analyses in mouse 
tissues where high LNA-i-miR-221  content 48 hours after the 
single active dose was demonstrated. The prolonged pres-
ence of LNA-i-miR-221 in tissues several weeks after the 
oligonucleotide have been cleared from the circulation indi-
cates cell specific uptake. We detected strong LNA-i-miR-221 
ISH signal in a variety of cell types. In the liver, stained cells 
were spindle-shaped cells which can be identified as vascu-
lar cells or macrophages. In the kidney, many tubular cells 
were positive and in the heart also spindle-shaped cells were 
positive. These observations indicate that different cell popu-
lations indeed bind and retain the LNA-i-miR-221. Further 
studies are needed to better characterize LNA-i-miR-221 
retaining cells. Interestingly, xenografted MM tumors accu-
mulate the LNA-i-miR-221 rapidly and the single 25 mg/kg i.p. 
dose reaches the tumor after 12 hours, even if these tumors 
are not well vascularized as compared to normal mouse vital 
organs.
Oligonucleotides are distinguished from other classes 
of pharmaceutical agents by both the mechanism of 
action and physical–chemical or pharmaceutical proper-
ties. PK studies of PS-oligonucleotides demonstrate that 
they are well absorbed from injection sites, rapidly dis-
tributed broadly to all peripheral tissues, and do not cross 
the BBB.44 However, PS-oligonucleotides have been used 
in some studies to knock-down central nervous system 
(CNS) proteins, for their characteristics to be transported 
across the BBB45,46 indicating that the PS-oligonucleotides 
injected peripherally can accumulate in the central nervous 
system in sufficient amounts to knockdown proteins in 
brain. Many reports showed that PS-oligonucleotides are 
transported across the BBB by saturable transporter even 
if at moderate rate to enter both the parenchymal space of 
the brain and the cerebrospinal fluid, and particularly high 
rate in hippocampus in comparison to the cerebral cortex 
or whole brain.47 In other studies, however the delivery of 
ASOs to the CNS has demonstrated important limitations 
since the BBB prevented blood-borne oligonucleotides from 
leaving the brain’s vascular space to enter the CNS.48,49 
The substitution of one nonbridging oxygen with the more 
hydrophobic sulfur atom, as in the case of PS nucleotides, 
increases both plasma stability and plasma protein binding 
and thus, tissue bioavailability and broad biodistribution. 
Our ISH analyses suggest that the 13-mer LNA-i-miR-221 
does not cross the normal BBB.
This observation further supports the framework for the 
clinical translation of the LNA-i-miR-221 molecule because 
long-term CNS toxicity is avoided. The safety toxicity pro-
file has been evaluated in our mouse and monkey studies. 
In fact, it has been described that ASOs with PS backbone 
exhibit a significant hybridization-independent toxicity pro-
file. The observed effects include increase of coagulation 
time, pro-inflammatory activity, activation of the complement 
pathway, and at higher concentrations, PS-ASOs lead to 
renal tubule changes and thrombocytopenia and induce a 
strong immunostimulatory response through their interac-
tions with Toll-like receptors.50 Data from our mouse study 
excluded damage of vital organs, since no changes in liver, 
kidney, and heart cellular morphology were observed after 
postmortem pathology. Furthermore, even p27 increase 
has been observed in liver, no apoptosis was detected by 
TUNEL assay. In monkey study, biochemical and hemato-
logic analysis did not demonstrate acute toxicity induced by 
LNA-i-miR-221 treatment, nor liver and renal failure, even 
at 10-folds increase of therapeutic dose. No immune stimu-
lation was induced in monkeys after systemic administra-
tion even at 10-folds increase. All findings from pathology 
and blood and serum evaluations, demonstrating absence 
of acute toxicity, were parallel by the lack of weight loss or 
behavioral changes by close monitoring of treated animals at 
all the investigated oligonucleotide doses.
In conclusion, our work firstly reports the PK and tissue 
bioavailability of LNA-i-miR-221 in two different animal mod-
els after i.v. or i.p. injection, which appears highly promising 
for translation in clinics. LNA-i-miR-221 is rapidly absorbed 
and completely distributed and excreted, with a short half-
life. We speculate that our PK results support the hypothesis 
of high plasma protein binding of LNA-i-miR-221, which may 
explain the reduced renal excretion and, therefore, facilitate 
uptake into peripheral tissues via high affinity receptors, 
resulting in increase of therapeutic efficacy. The well toler-
ated dose of 25 mg/kg in mouse, equivalent to 8.75 mg/kg 
in monkey, is recommended for the dosage calculation for 
animal treatment in regulatory toxicity studies and for the 
design of an early clinical trial. On the basis of our findings 
it will be reasonable to consider intensive loading schedule, 
for instance by consecutive daily administration, in order to 
maximize the tissue distribution up to tolerated doses in dose 
finding early clinical trials.
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Mouse study. Different doses of LNA-i-miR-221 were evalu-
ated in NCI-H929 xenografted NOD.SCID mice. Two differ-
ent in vivo experiments were performed for LNA-i-miR-221 
detection by ISH. In the first experiment, mice were random-
ized into two groups and treated i.p. with a single dose of 
25 mg/kg LNA-i-miR-221, defined as therapeutic dose, or 
scramble control. Tumors and organs including liver, kidney, 
heart, bone marrow, brain, and tumor were collected after 2 
and 7 days from treatment. In a second in vivo experiment 
animals received a cycle (days 1, 4, 8, 15, and 22) of LNA-i-
miR-221 i.p. treatment at two different doses (25 and 100 mg/
kg) including saline control group. MM xenografted tumors 
and organs were collected after 1 and 3 weeks from the last 
dose. All specimens were immediately formalin-fixed and 
paraffin embedded in 24–36 hours. For PK study mice were 
treated i.p. with a single dose of 25 mg/kg LNA-i-miR-221, or 
saline as control and blood sampling were performed 90 min-
utes and 3, 4.5, 6, 12, and 24 hours following injection into 
a K
2EDTA tube and immediately placed on ice. Thereafter, 
plasma was obtained from the blood sample by centrifuga-
tion at 3,000×g for 10 minutes at +4 °C. The resulting plasma 
was stored at approximately −80°C until analysis.
Tissue samples. Mouse tissues and organs were collected 
after treatment at different time points. In brief, after removal 
from mice, the tissues/organs were dissected into appro-
priate specimens, formalin fixed for 24–36 hours and then 
embedded in paraffin at the Pathology Unit (Hospital Lame-
zia Terme, Calabria, Italy). Five micrometer-thick serial sec-
tions were obtained from all paraffin samples for standard 
hematoxylin and eosin, and immunohistochemistry staining, 
for immunofluorescence assay and for ISH analysis. This was 
performed at Bioneer (Horsholm, Denmark).
LNA probes. Double FAM-labeled LNA:DNA chimeric anti-
sense probes (hereafter referred to LNA probes) were all 
obtained from Exiqon (Exiqon, Vedbaek, Denmark). LNA 
probes included the antisense probe to the therapeutic 
LNA-i-miR-221 named miR-221i (sequence 3′-AGCTACATT-
GTCTGTA-5′, DNA/LNA probe, Tm = 79 °C, LNA content 
= 31%), miR-126-3p (3′-CATTATTACTCACGGTACGA-5′, 
DNA/LNA probe, Tm = 84 °C, LNA content = 40%), used as 
positive control, and a scramble probe (3′-tgtaacacgtctatac-
gccca-5′, Tm = 87 °C, LNA content = 33%), as negative con-
trol.51 The melting temperatures for all the above indicated 
LNA probes are RNA-Tm, and are predicted (according to 
Exiqon’s software tools) toward complementary RNA oligo-
nucleotides using spectrophotometer. The Tm for the inter-
action between the LNA molecule, LNA-i-miR-221, and the 
LNA probe, miR-221i, may well be higher than predicted by 
the software because of the LNA content in both sequences.
In situ hybridization. Five µm-thick paraffin sections were 
obtained and processed for LNA-based ISH essentially as 
previously described.52,53 In brief, the sections were depar-
affinized in xylene, and then the following steps were per-
formed in a Tecan Freedom Evo automated hybridization 
instrument (Tecan, Mannedorf, Switzerland): pre-digestion 
with 3 µg/ml proteinase-K (for 8 minutes at 37 °C), prehy-
bridization and ISH in Exiqon hybridization buffer (Exiqon) 
at 55 °C for 15 minutes and 60 minutes, respectively, strin-
gent washes with SSC buffers, probe detection using alkaline 
phosphatase-conjugated anti-FAM sheep immunoglobulin 
(Roche Diagnostics, Manheim, Germany) for 30 minutes, 
4-nitro-blue tetrazolium, and 5-bromo-4-chloro-30-indolyl-
phosphate substrate incubation for 60 minutes. Finally, 
sections were counterstained with nuclear fast red (Vector 
Laboratories, Burlingname, CA) and mounted using Eukitt 
mounting medium. The three LNA probes, LNA-i-miR-221, 
miR-126, and scramble, were incubated on tissue sections 
during the ISH step at 10, 30 and 20 nmol/l.
Immunohistochemistry and fluorescence assays. For each 
case 4 µm-thick serial sections were cut from a representative 
block of formalin fixed, paraffin-embedded tissue, mounted on 
acid-cleaned glass slides, and heated at 55 °C for 60 minutes. 
Slides were, dewaxed with xylene, and processed for hematox-
ylin and eosin and immunohistochemistry. All the procedures 
were performed at room temperature. Immunohistochemical 
evaluation of anti-p27 was performed using the LSAB+ Sys-
tem HRP (DakoEnvision System, CA), followed by the addi-
tion of 3,3′-diaminobenzidine as a chromogen. Endogenous 
peroxidase activity was quenched for 5 minutes in 3% hydro-
gen peroxidase, and the slides were rinsed in wash solution 
(TBST, 0.05 mol/l Tris Buffered Saline with Tween20). Antigen 
retrieval was performed with EDTA buffer pH 9 for 30 min-
utes at 98 °C. Slides were washed three times in phosphate-
buffered saline (PBS; pH 7.4) for 5  minutes. Immunostaining 
was performed using a purified mouse monoclonal antibody 
anti-p27 (clone 57/Kip-1/27, diluted 1:150, BD Biosciences, 
CA) and a purified mouse monoclonal antibody ki67 (clone 
MIB-1, 1:150 dilution, DakoEnvision System) for 1 hour at 25 
°C. Sections were finally counterstained with hematoxylin. 
Negative controls were performed in each run by substituting 
primary antibodies with antibodies with irrelevant specificity 
but of the same isotype of the primary antibodies. The apop-
tosis evaluation was performed by TUNEL Assay, designed 
for the specific detection and quantitation of apoptotic cells 
(DeadEnd Fluorometric Tunel System, Promega Corpora-
tion, Madison, WI). Deparaffined slides were washed twice in 
PBS for 5 minutes each time, permeabilized and equilibrated 
with an Equilibration buffer at room temperature for 10 min-
utes. On the Slides were added a Terminal Deoxynucleotidyl 
Transferase reaction mix, covered with plastic coverslips to 
ensure even distribution of the mix and incubate for 60 min-
utes at 37°C in a humidified chamber avoid exposure to light. 
The reaction was stopped immerging slides in 2× SSC for 15 
minutes. Then slides were washed three times in PBS for 5 
minutes each time. Finally all nuclei were counterstained with 
4',6-diamidino-2-phenylindole (DAPI). The fragmented DNA 
of apoptotic cells by catalytically incorporating fluorescein-
12-dUTP at 3′-OH DNA ends using Terminal Deoxynucleo-
tidyl Transferase were analyzed by fluorescence microscopy.
Determination of LNA-i-miR-221 in plasma mouse samples 
by LC-MS/MS. The samples were analyzed in Aptuit (Verona, 
Italy). Ultra-high pressure liquid chromatography (UHPLC) 
after solid-phase extraction was used. To obtain LNA-miR-221 
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inhibitor from mouse plasma, an aliquot of 120 µl of these 
samples were diluted with 120 µl of 0.1 mol/l triethylammo-
nium acetate (TEAAC) buffer pH = 7 and gently mixed. After, 
200 µl of samples were loaded onto a µ-elution HLB SPE 
96-well plate, which were preactivated and preconditioned 
using 200 µl of acetonitrile followed by 200 µl of 0.1 mol/l 
TEAAC buffer pH = 7. Then, samples were drawn through 
using a low vacuum. SPE wells were first washed using 200 µl 
0.1 mol/l TEAAC buffer and then 200µl of water. The wells 
were eluted two times using 200 µl 0.1 mol/l TEAAC buffer 
pH 7/acetonitrile (30:70, v/v). The eluates after evaporation 
to dryness, at ~25 °C, under nitrogen were reconstituted with 
75µl of mobile phase A. An aliquot of 10 µl were injected 
into LC-MS/MS system. Then a tandem mass spectrometry 
(MS/MS) by a triple quadripole Turbo Ion Spray ionization 
source permitted the detection of very low quantity (25 ng/
ml) of LNA-miR-221 inhibitor in mouse plasma. For calibra-
tion curve, a weighed linear regression function (1/x2) was 
used to fit calibration lines, and consequently, to calculate 
LNA-miR-221 inhibitor concentrations in the calibration range 
25–2,500 ng/ml, with at least 75% of back-calculated concen-
trations within 15% accuracy. Mouse plasma concentrations 
obtained at various sampling time-points were used to calcu-
late the time to achieve maximum plasma concentration at 
first experimental observation (Tmax), the maximum plasma 
concentration at the first observation (Cmax), the area under 
the curve up to the last (Tlast 6 hours) measurable concentra-
tion (AUClast), and the elimination half-life (t1/2).
Nonhuman primates study. Number seven male purpose-
bred Cynomolgus monkeys (Macaca fascicularis) were 
selected for entry into this study. The animals were allowed 
to acclimatize to the CiToxLab (Evreux, France) primate toxi-
cology accommodation for a period of 4 weeks before the 
commencement of the study. All animals were dewormed 
by CiToxLab. The animals were selected for entry into the 
study based on the results of a satisfactory preliminary health 
screening. The route of administration was i.v. bolus injection 
into the saphenous vein. The control group was treated with 
saline (sodium chloride 0.9%) as well the dilution of the mol-
ecule. The quantity of dose formulation administered to each 
animal was adjusted according to the most recently recorded 
body weight. A constant dosage-volume of 1 ml/kg was used. 
The administration system was weighed before and after 
dosing in order to determine the precise quantity of test item 
administered. At the beginning of the study, the animals were 
33–58 months old and they had a mean body weight of 4.1 kg 
(range: 3.2–4.8 kg) (groups 1–4) and 3.1 kg on Day 7 (group 
5). After allocation to the study, the animals were acclimated 
to the study conditions for a period of 7 days before the 
beginning of the treatment period. During this period, pre-
treatment investigations were performed. Two supernumer-
ary animals were allocated to the study and acclimated, in 
order to permit the selection and/or replacement of individu-
als. During the pretreatment period, five male animals were 
selected according to the results of clinical and laboratory 
examinations. The animals were individually identified by a 
subcutaneous microchip for automated identification at the 
breeder’s facility. At the beginning of the study, each animal 
received a unique CiToxLab France identity number and were 
housed in a dedicated primate unit. The animal room condi-
tions were set with a temperature range 22 ± 3 °C, relative 
humidity of 50 ± 30%, light/dark cycle of 12 hours/12 hours, 
and ventilation range between 8 and 15 cycles/hour of fil-
tered, nonrecycled air.
Toxicity profile of LNA-i-miR-221 in nonhuman primates. Five 
male Cynomolgus monkeys were allocated in the study. The 
first four animals (#1–#4) received LNA-i-miR-221 on days 
1, 4, 8, 15, and 22, respectively at 0, 2.5, 6.25 or 8.75 mg/kg/
day by i.v. infusion (bolus) in order to determine the maximum 
tolerated dose. On day 22, the last animal (#5) received the 
highest dose (8.75 mg/kg) to perform PKs investigations in 
plasma and urine. Animals were checked at least twice a day 
for mortality and clinical signs, including weekends. Special 
attention was paid to skin, eyes, and mucous membranes 
as well as injection sites. Heart rate was evaluated using a 
stethoscope in a calm environment over 10 seconds and 
then multiply by six in order to determine approximate heart 
rate of the animals in beats per minute. Body weight was 
recorded once before the beginning of the treatment period 
(once in pretest, day 5), on the first day of treatment and 
then, on each day of the first two treatments for the animals 
of groups 1–4 and on the eve of the day of treatment for the 
following administration including the animal of the group 5. 
Blood samples for hematology and blood biochemistry 
investigations were collected as following: in pretest (day 5), 
predose prior the first administration, on days 1, 4, 8, 15, 
and 22 from animals of groups 1–4. Blood and urine were 
collected from animal #5 only in order to establish PKs pro-
file of the LNA-i-miR-221, accordingly: (i) for blood sampling, 
before treatment 0, 30, and 60 minutes, 2, 4, 6, 12, 24, and 
48 hours following i.v. injection of LNA-i-miR-221 and (ii) for 
urine sampling, intervals (0–2 hours), (2—6 hours), (6—12 
hours), (12 —24 hours), and (24—48 hours) after i.v. admin-
istration. Before blood collection, the animals were deprived 
of food for an overnight period of at least 14 hours. Blood 
samples were collected without anesthetic from an appropri-
ate vein into BD Microtainer® (K
2EDTA) tubes for the ADVIA 
120 Hematology analyzer; into sodium citrate tubes for ACL 
Elite Pro blood coagulation analyzer; into lithium heparin 
tubes for ADVIA 1,800 blood biochemistry analyzer. For PK 
analysis, venous blood (~0.5 ml) was taken from an appropri-
ate vein of animal #5 into a K2EDTA tube and immediately 
placed on ice. Thereafter, plasma was obtained from the 
blood sample by centrifugation at 3,000×g for 10 minutes at 
+4 °C (start of centrifugation within 30 minutes after blood 
sampling). The resulting plasma was stored at ~−80 °C until 
analysis. Urine collection was performed for the determina-
tion of LNA-i-miR-221 levels from animal #5. To increase 
diuresis, drinking water (~15 ml) was administered (gavage) 
2 hours after treatment and prior to the beginning of urine 
collection. All samples were collected on ice. Urine samples 
were weighed and the volumes recorded, then stored at 
−80 °C until analysis. Plasma collected at time 0, 24, and 48 
hours after single highest dose were used for TNF-α, IFN-γ, 
IL-4, IL-6, IL-8 and MCP-1 inflammatory cytokines measure-
ment, by using the flex-set BD cytometric bead array (BD 
CBA flex set; BD Biosciences, Franklin Lakes, NJ) assay, 
according to producer guidelines.
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Pharmacokinetic profile of LNA-i-miR-221 in nonhuman 
primates. The determination of LNA-i-miR-221 in plasma 
monkey samples were performed according to LC-MS/
MS protocols before described for mouse plasma. The 
determination of LNA-i-miR-221 in urine monkey samples 
was performed by ultra-high pressure liquid chromatog-
raphy (UHPLC) after solid-phase extraction. To obtain 
LNA-miR-221 inhibitor from urine, an aliquots of 220 µl of 
the urine samples were diluted with 220 µl of 0.1 mol/l Tri-
ethylammonium acetate (TEAAC) buffer pH = 6 with acetic 
acid (10%) and gently mixed. 400 µl of mixed samples were 
loaded onto a conditioned µ-elution HLB SPE 96-well plate. 
The SPE wells were activated and conditioned using 200 
µl of acetonitrile followed by 200 µl of 0.1 mol/l TEAAC buf-
fer pH = 6. After loading of the mixed samples and drawn 
through using a low vacuum, the SPE wells were washed 
using first 200 µl 0.1 mol/l TEAAC buffer pH = 6 and then 200 
µl of water. The compound was eluted two times using 200 
µl of 0.1 mol/l TEAAC buffer pH 6/acetonitrile (30:70, v/v). 
The eluates were leave to dry by evaporation approximately 
at 25 °C under nitrogen, then were reconstituted with 50 µl 
of mobile phase A. Aliquots of 10 µl were injected into the 
LC-MS/MS system. A tandem mass spectrometry (MS/MS) 
equipped with a triple quadripole API4,000 (Sciex) and Turbo 
Ion Spray ionization source in positive ion mode, allowed the 
detection of very low quantity (25 ng/ml) of LNA-miR-221 
inhibitor in mouse plasma. For calibration curve, a weighed 
linear regression function (1/x2) was used to fit calibration 
lines and consequently to calculate LNA-miR-221 inhibitor 
concentration in the calibration range 75–5,000 ng/ml, with 
at least 75% of back-calculated concentrations within 20% 
accuracy. The limit of quantification in Cynomolgus  monkey 
urine was 75 ng/ml. The monkey’s plasma concentrations 
obtained at various sampling time points were used to calcu-
late the time to achieve the maximum plasma concentration 
(Tmax), the initial concentration, extrapolated at dosing time 
(C0), the maximum plasma concentration (Cmax) and the area 
under the curve up to the last (Tlast 48 hours) measurable 
concentration (AUClast).
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